A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors

Trial Profile

A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Ribociclib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Array BioPharma; Novartis
  • Most Recent Events

    • 06 Jun 2017 Results assessing safety and preliminary efficacy (n=63), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 17 Feb 2017 Planned End Date changed from 1 Jan 2018 to 31 Dec 2018.
    • 05 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top